[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100348556":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":41,"locations":48,"responsibleParty":67,"collaborators":46,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":46,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":46,"studyType":83,"phases":84,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":51,"whyStopped":46,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Hospital Israelita Albert Einstein","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Post Cyclophosphamide","EXPERIMENTAL","Cyclophosphamide 50 mg\u002FKg on days +3 and +4 AND Calcineurin Inhibitor from day +5 AND Mycofenolate Mofetil from day +5 until day +35",[13],"Drug: Cyclophosphamide",{"label":15,"type":16,"description":17,"interventionNames":18},"Thymoglobulin (ATG)","ACTIVE_COMPARATOR","Thymoglobulin (ATG) total dose 5 mg\u002FKg from day -4 until day -1 AND Calcineurin Inhibitor from day +5 AND Methotrexate on days +1, +3, +6 and +11",[19],"Drug: ATG",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Cyclophosphamide","Cyclophosphamide 1000 mg\u002Fflask",[9],[27],"Cytoxan",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"ATG","Antihuman T-Lymphocyte Immune Globulin 25 mg\u002Fflask",[15],[33],"Thymoglobulin",[35,38],{"name":36,"affiliation":5,"role":37},"Andreza A Feitosa Ribeiro, PhD","PRINCIPAL_INVESTIGATOR",{"name":39,"affiliation":5,"role":40},"Nelson Hamerschlak, PhD","STUDY_CHAIR",[42],{"name":43,"role":44,"phone":45,"phoneExt":46,"email":47},"Andreza A Feitosa Ribeiro","CONTACT","+5511992512523",null,"andreza.ribeiro@einstein.br",[49],{"facility":50,"status":51,"city":52,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Hospita Israelita Albert Eintein","RECRUITING","São Paulo","05652-900","Brazil","BR",{"type":57,"coordinates":58},"Point",[59,60],-46.63611,-23.5475,{"lat":60,"lon":59},[63],{"name":64,"role":44,"phone":65,"phoneExt":46,"email":66},"Mirele Santos","+112151-0305","mirele.santos@einstein.br",{"type":37,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":46,"oldOrganization":46},"Andreza Alice Feitosa Ribeiro","Assistant Physician specialist in Hematopoietic Stem Transplantation, Principal Investigator","100348556","phase-2-post-transplant-cyclophosphamide-in-matched-unrelated-donor-stem-cell-transplantation-for-hematological-malignancies-100348556",false,"NCT03818334","Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies","Use of Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies, a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Men and Women of Any Age\n* Indication for an HSCT without matched sibling donor\n* Have a matched unrelated donor (HLA 10 x 10 or 9 x 10)\n* Hematological malignancy\n\nExclusion Criteria:\n\n* Acute leukemias not in complete response (that is \\> 5% blast in the bone marrow)\n* Chemorefractory lymphoproliferative disease\n* Active uncontrolled infection\n* HCT-CI \\> 3\n* Severe organic disfunction (heart ejection fraction \\\u003C 45%, glomerular filtration rate \\\u003C 50 mL.hour, pulmonary DLCO \\\u003C 50%)\n* Previous allogeneic bone marrow transplantation\n* Contraindication to cyclophosphamide or ATG","ALL","1 Year","75 Years",{"count":81,"type":82},50,"ESTIMATED","INTERVENTIONAL",[85,86],"PHASE2","PHASE3","This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).",[89,90,91,92,93],"Bone Marrow Transplant Complications","Graft Versus Host Disease","Infection Viral","Engraft Failure","Immunologic Suppression",[95,96,97],"Bone Marrow Transplantation","Hematological Malignancies","Post-Cy","2019-01-31",{"date":100,"type":101},"2019-02-01","ACTUAL",{"date":103,"type":101},"2018-11-06",{"date":105,"type":82},"2026-11-01",{"name":5,"class":6},1]